Reading Guide:

Lyra therapeutics promotes innovative treatments in the field of CRS.

（Source: Network）

• Lyra is a clinical biotech based in Watertown, Massachusetts.

• Xtreo technology platform is used for drug delivery, single administration and continuous release.

• The company is committed to developing a combination of drugs and instruments to treat local tissue diseases of eye, ear and throat.

At present, the company mainly focuses on the treatment of chronic sinusitis (CRS). In the United States, 12% of the population has sinusitis, and about 14 million people have chronic sinusitis and suffer from persistent symptoms.

（Source: Network）

At present, the first-line treatment drugs for chronic sinusitis are nasal spray steroids or oral steroids, but nasal spray steroids have two defects: one is that the drugs can not reach the deep inflammatory site through the nasal cavity, and the other is that they need to be administered many times a day, which brings inconvenience to patients. The further use of oral steroids is limited due to the large side effects. Therefore, the field of chronic sinusitis needs more effective and more compliant therapeutic drugs, and there are unmet clinical needs in this field.

（Source: Network）

Lyra uses the proprietary platform technology xtreo to deliver steroids to inflammatory sites and can release them for 6 months, which solves the shortage of current drug treatment.
Xtreo technology includes three parts: biocompatible mesh stent (to maximize the drug release surface area), elastic matrix and drug release polymer (to achieve constant drug release).

（Source: Network）

At present, the company has two varieties under research, lyr-210 and lyr-220. The active ingredient delivered by lyr-210 and lyr-220 is mometasone furoate. The difference is that lyr-210 is used in the non-surgical population and lyr-220 is used in the post-surgical population.

（Source: Network）

• LYR-210

Lyr-210 is currently in phase 3 and is under clinical recruitment. The clinical phase 2 trial named lantern stu (nct04041609) (starting in 2019 and ending in February 2021, a total of 71 patients were recruited, the delivery dose of furfural mometasone was 7500ug, the primary endpoint was 4 weeks of clinical symptom improvement, and the secondary endpoint was 24 weeks of quality of life improvement). The results showed that 70% of patients reached the primary clinical endpoint.
In 2021, Lyra and Liantuo biology reached a strategic cooperation and exclusive license agreement. The two sides will work together to develop and commercialize lyr-210 in Greater China (Chinese Mainland, Hong Kong, Macao and Taiwan), South Korea, Singapore and Thailand.

• LYR-220

Lyr-210 is currently in phase 3 and is under clinical recruitment. The clinical phase 2 trial named lantern stu (nct04041609) (starting in 2019 and ending in February 2021, a total of 71 patients were recruited, the delivery dose of furfural mometasone was 7500ug, the primary endpoint was 4 weeks of clinical symptom improvement, and the secondary endpoint was 24 weeks of quality of life improvement). The results showed that 70% of patients reached the primary clinical endpoint.
In 2021, Lyra and Liantuo biology reached a strategic cooperation and exclusive license agreement. The two sides will work together to develop and commercialize lyr-210 in Greater China (Chinese Mainland, Hong Kong, Macao and Taiwan), South Korea, Singapore and Thailand.

Reference material：

• https://lyratherapeutics.com/

• https://seekingalpha.com/article/4502632-lyra-therapeutics-first-look

• https://www.lianbio.com/cn/news/lyra-therapeutics-and-lianbio-announce-strategic-partnership-and-exclusive-license-agreement-to-develop-and-commercialize-lyr210-in-greater-china-and-other-asian-markets/